CCL2 and renal fibrosis: The basic principle of targeting MCP-1/CCR2 to treat related diseases in human beings is to use drugs to block MCP-1 or CCR2, inhibit the activation and conduction of MCP-1/CCR2 axis, thereby reducing the inflammatory cells and pro-inflammatory cytokines.[8,9] In addition, the MCP-1/CCR2 axis is also a very important participant in chemokine signaling in renal fibrosis.